<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04432857</url>
  </required_header>
  <id_info>
    <org_study_id>AN0025S0103</org_study_id>
    <secondary_id>2019-003960-37</secondary_id>
    <secondary_id>Keynote 879</secondary_id>
    <secondary_id>MK3475-879</secondary_id>
    <nct_id>NCT04432857</nct_id>
  </id_info>
  <brief_title>AN0025 and Pembrolizumab Combination in Advanced Solid Tumors</brief_title>
  <official_title>An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adlai Nortye Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Adlai Nortye Biopharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, phase Ib study to evaluate the safety and preliminary&#xD;
      efficacy of AN0025 in combination with pembrolizumab in patients with locally&#xD;
      advanced/metastatic tumors. It will include a dose-limiting toxicity observation phase&#xD;
      followed by an expansion phase. All enrolled patients will be treated with AN0025 and&#xD;
      Pembrolizumab until the patient experiences disease progression, unacceptable toxicity or&#xD;
      withdraws consent, or for a maximum of 35 cycles (approximately 2 years). The dose of&#xD;
      pembrolizumab will remain constant at 200 mg every 3 weeks (Q3W) for each dose level of&#xD;
      AN0025 and in each cohort.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Measure</measure>
    <time_frame>3 weeks</time_frame>
    <description>Number of participants with Dose Limiting Toxicities (DLTs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR and Progression-Free Survival (PFS) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy by PD-L1 expression</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Triple-negative Breast Cancer</condition>
  <condition>NSCLC, Squamous or Non-Squamous</condition>
  <condition>Urothelial Carcinoma of the Bladder</condition>
  <condition>Microsatellite Stable (MSS) Colorectal Cancer (CRC)</condition>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Ph1a: Urothelial carcinoma of the bladder and NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Urothelial carcinoma of the bladder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Non-Small Cell Lung Cancer (NSCLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Triple-negative breast cancer (TNBC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Cervical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Microsatellite Stable (MSS) Colorectal Cancer (CRC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN0025</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Ph1a: Urothelial carcinoma of the bladder and NSCLC</arm_group_label>
    <arm_group_label>Phase 1b: Cervical</arm_group_label>
    <arm_group_label>Phase 1b: Microsatellite Stable (MSS) Colorectal Cancer (CRC)</arm_group_label>
    <arm_group_label>Phase 1b: Non-Small Cell Lung Cancer (NSCLC)</arm_group_label>
    <arm_group_label>Phase 1b: Triple-negative breast cancer (TNBC)</arm_group_label>
    <arm_group_label>Phase 1b: Urothelial carcinoma of the bladder</arm_group_label>
    <other_name>E7046</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Infusion</description>
    <arm_group_label>Ph1a: Urothelial carcinoma of the bladder and NSCLC</arm_group_label>
    <arm_group_label>Phase 1b: Cervical</arm_group_label>
    <arm_group_label>Phase 1b: Microsatellite Stable (MSS) Colorectal Cancer (CRC)</arm_group_label>
    <arm_group_label>Phase 1b: Non-Small Cell Lung Cancer (NSCLC)</arm_group_label>
    <arm_group_label>Phase 1b: Triple-negative breast cancer (TNBC)</arm_group_label>
    <arm_group_label>Phase 1b: Urothelial carcinoma of the bladder</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>MK3475-879</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.&#xD;
&#xD;
        Diagnosed with histologically confirmed locally advanced and nonresectable, or metastatic&#xD;
        disease.&#xD;
&#xD;
        Phase 1a:&#xD;
&#xD;
        Patients with urothelial carcinoma of the bladder, or squamous or non-Squamous NSCLC&#xD;
&#xD;
        Phase 1b Expansion Cohort:&#xD;
&#xD;
        Patients diagnosed with one of the following tumor types:&#xD;
&#xD;
        A. Urothelial carcinoma of the bladder B. NSCLC, Squamous or Non-Squamous C. TNBC D.&#xD;
        Cervical cancer E. MSS CRC&#xD;
&#xD;
        Have progressed on treatment with an anti-PD-1/PD-L1monoclonal antibody (mAb) administered&#xD;
        either as monotherapy, or in combination with other checkpoint inhibitors or other&#xD;
        therapies (phase 1a, phase 1b cohort A or B) or with no prior anti-PD-1/PD-L1 therapy and&#xD;
        failed standard of care treatment (phase 1b cohort C, D, or E).&#xD;
&#xD;
        Have received no more than 3 prior lines of systemic therapy for advanced disease.&#xD;
&#xD;
        Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a&#xD;
        tumor lesion not previously irradiated.&#xD;
&#xD;
        Left ventricular ejection fraction (LVEF) greater than 50% on echocardiography or multiple&#xD;
        gated acquisition (MUGA) scan.&#xD;
&#xD;
        Have adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Have been discontinued treatment due to a Grade 3 or higher immune-related (irAE) from&#xD;
        prior anti-PD-1or anti-PD-L1, or with an agent directed to another stimulatory or&#xD;
        co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137)&#xD;
&#xD;
        Have received prior systemic anti-cancer therapy including investigational agents within 4&#xD;
        weeks or 5 half-lives, whichever is shorter prior to treatment.&#xD;
&#xD;
        Have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in&#xD;
        dosing exceeding 10 mg daily of prednisone equivalent) or any other form of&#xD;
        immunosuppressive therapy within 7 days prior to the first dose of study drug.&#xD;
&#xD;
        With a history of another primary malignancy within the past 2 years, with the exception of&#xD;
        basal or squamous cell skin cancer, or carcinoma in situ of the cervix or breast that has&#xD;
        undergone potentially curative therapy.&#xD;
&#xD;
        Have known active CNS metastases and/or carcinomatous meningitis.&#xD;
&#xD;
        Participants with known human immunodeficiency virus (HIV) and/or history of Hepatitis B or&#xD;
        C infections, or known to be positive for Hepatitis B antigen (HBsAg)/ Hepatitis B virus&#xD;
        (HBV) DNA or Hepatitis C Antibody or RNA.&#xD;
&#xD;
        Prolongation of corrected QT.&#xD;
&#xD;
        Significant cardiovascular impairment.&#xD;
&#xD;
        Inability to take oral medication, or malabsorption syndrome or any other uncontrolled&#xD;
        gastrointestinal condition (eg, nausea, diarrhea, or vomiting) that might impair the&#xD;
        bioavailability of AN0025.&#xD;
&#xD;
        Is pregnant or breastfeeding or expecting to conceive or father children within the&#xD;
        projected duration of the study, starting with the screening visit through 120 days after&#xD;
        the last dose of study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan Lautermilch, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>ADLAI NORTYE USA INC.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathan Lautermilch, Ph.D.</last_name>
    <phone>1-848-230-7430</phone>
    <phone_ext>414</phone_ext>
    <email>Nathan.Lautermilch@adlainortye.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hong, MD</last_name>
      <phone>713-563-5844</phone>
      <email>dshong@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arun Athithan</last_name>
      <email>Arun.Athithan@hci.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Sharry</last_name>
      <email>Susan.Sharry@hci.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Wallace Akerley, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Drake, BSN, RN</last_name>
      <phone>434-297-7782</phone>
    </contact>
    <contact_backup>
      <email>JD4CX@hscmail.mcc.virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Reilley, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marielle BOSSE-PLATIERE</last_name>
      <phone>33 (0)4 69 85 61 51</phone>
      <email>marielle.bosse-platiere@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Cassier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Paris</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Assia HAMAMOUCHE</last_name>
      <phone>(+33) 1 42 11 56 54</phone>
      <email>assia.hamamouche@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Aurélien Marabelle, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 11, 2020</study_first_submitted>
  <study_first_submitted_qc>June 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

